Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Xenopus laevis• Among most efficient remyelinating compounds; bell-shaped dose-response (25, 26)Cuprizone• ↑ Remyelinated axons 2.19-fold; ↑ pro: regenerative microglia; ↑ oligodendroglial differentiation markers (26)• ↑ MBP and MAG expression; ↑ OLIG2+ density; promotes OPC differentiation over proliferation (27)• + Vitamin D3: ↑ myelin recovery; ↓ M1 microglia in corpus callosum (28)Cuprizone + Rapamycin• 25 to 40% ↓ myelin protein loss (demyelinating phase); ~25% ↑ myelinated axons by EM (remyelinating phase) (6)EAE-Optic Neuritis (EAEON)• ↓ Clinical scores, retinal degeneration, optic nerve demyelination; remyelinating effect confirmed with therapeutic (post-onset) dosing (26)
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Publisher article type: review-article
Source: Publisher publication metadata.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies
Review / evidence synthesis · Frontiers in Immunology · 2026
Original publication title
Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies
Copyright © 2026 Ricigliano.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Sphingosine-1-phosphate (S1P) receptor modulators are a class of therapeutic agents used for the treatment of multiple sclerosis (MS). There are four S1P modulators currently approved by the Food and Drug Administration/European Medical Agency (FDA/EMA): fingolimod, siponimod, ponesimod, and ozanimod. Beyond their well-established immunomodulatory properties, accumulating evidence suggests that these molecules exert direct effects on oligodendrocyte progenitor cells (OPCs) and mature oligodendrocytes, promoting myelin repair through multiple mechanisms. In vitro studies show enhanced OPC differentiation and process extension, while in vivo models demonstrate increased remyelination, improved myelin protein expression, and functional recovery.
Imaging studies in people with MS suggest increased myelin repair over time. Potential mechanisms underlying the observed effects involve selective modulation of S1P receptor subtypes (particularly S1PR1, S1PR3, and S1PR5). This comprehensive review summarizes available preclinical and clinical evidence on the role of S1P modulators in remyelination in the context of MS and shows that fingolimod, siponimod and ponesimod possess emerging promise in this field.
Authors’ abstract
Sphingosine-1-phosphate (S1P) receptor modulators are a class of therapeutic agents used for the treatment of multiple sclerosis (MS). There are four S1P modulators currently approved by the Food and Drug Administration/European Medical Agency (FDA/EMA): fingolimod, siponimod, ponesimod, and ozanimod. Beyond their well-established immunomodulatory properties, accumulating evidence suggests that these molecules exert direct effects on oligodendrocyte progenitor cells (OPCs) and mature oligodendrocytes, promoting myelin repair through multiple mechanisms. In vitro studies show enhanced OPC differentiation and process extension, while in vivo models demonstrate increased remyelination, improved myelin protein expression, and functional recovery.
Imaging studies in people with MS suggest increased myelin repair over time. Potential mechanisms underlying the observed effects involve selective modulation of S1P receptor subtypes (particularly S1PR1, S1PR3, and S1PR5). This comprehensive review summarizes available preclinical and clinical evidence on the role of S1P modulators in remyelination in the context of MS and shows that fingolimod, siponimod and ponesimod possess emerging promise in this field.
Publication and source details
Original title: Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies
Vito A.G. Ricigliano
Frontiers in Immunology · 2026
* Correspondence: Vito A.G. Ricigliano, v.ricigliano@ghne.frCopyright © 2026 Ricigliano.2026Riciglianohttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:42:20.967427+00:00
DOI: 10.3389/fimmu.2026.1895118 · PMC13598573